银杏酮酯分散片联合罗格列酮对缺血性脑卒中患者疗效及神经功能的影响  

Therapeutic effect of Ginkgo ketoester dispersible tablet combined rosiglitazone on patients with ischemic stroke and its influence on neurological function

作　　者：周刚[1] 李泉 ZHOU Gang;LI Quan(Department of Neurology,Central Hospital of Huanggang City,Huanggang,Hubei,438000,China)

机构地区：[1]湖北省黄冈市中心医院神经内科,湖北黄冈438000

出　　处：《心血管康复医学杂志》2018年第4期454-458,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:观察银杏酮酯分散片联合罗格列酮对缺血性脑卒中患者的疗效及神经功能的影响。方法:选择我院收治的缺血性脑卒中患者102例作为研究对象。患者被随机均分为罗格列酮组和联合治疗组(接受罗格列酮联合银杏酮酯分散片治疗),两组持续治疗4周。观察比较两组疗效、治疗前后美国国立卫生研究所卒中神经功能缺损程度评分量表(NIHSS)评分、日常生活能力量表(ADL)评分以及血流动力学指标的变化。结果:联合治疗组总有效率显著高于罗格列酮组(90.20%比74.51%),P=0.038。与治疗前比较,治疗后两组ADL评分显著升高,NIHSS评分、全血黏度高切、全血黏度低切、红细胞压积、纤维蛋白原(Fg)和血浆黏度水平均显著降低,P均=0.001;与罗格列酮组比较,联合治疗组治疗后ADL评分[(38.64±6.29)分比(45.49±6.32)分]升高更显著,NIHSS评分[(16.59±3.41)分比(13.74±3.18)分]、全血黏度高切[(6.27±0.51)mPa·s比(5.49±0.53)mPa·s]、全血黏度低切[(10.35±0.64)mPa·s比(9.28±0.67)mPa·s]、红细胞压积[(42.37±3.19)%比(39.28±3.34)%]、Fg[(4.38±0.27)g/L比(3.26±0.24)g/L]和血浆黏度[(1.35±0.18)mPa·s比(1.19±0.17)mPa·s]水平降低更显著,P均=0.001。结论:银杏酮酯分散片联合罗格列酮能够有效改善缺血性脑卒中患者神经功能和血液流变学,提高临床疗效,值得推广。Objective： To observe therapeutic effect of Ginkgo ketoester dispersible tablet combined rosiglitazone on patients with ischemic stroke and its influence on neurological function. Methods： A total of 102 patients with ische- mic stroke treated in our hospital were selected. Patients were randomly and equally divided into rosiglitazone group and combined treatment group （received rosiglitazone combined Ginkgo ketoester dispersible tablet）, both groups were continuously treated for four weeks. Therapeutic effect, United States national institutes of health stroke score （NIHSS）, score of activity of daily living scale （ADL） and observed and compared between two groups. Results： Total hemodynamic indexes before and after treatment were effective rate of combined treatment group was signifi- cantly higher than that of rosiglitazone group （90.20% vs. 74.51%）, P = 0.038. Compared with before treatment, after treatment, there was significant rise in ADL score, and significant reductions in NIHSS score, whole blood high shear viscosity, whole blood low shear viscosity, hematocrit, fibrinogen （Fg） and plasma viscosity in two groups, P = 0. 001 all. Compared with rosiglitazone group after treatment, there was significant rise in ADL score [ （38. 64＋ 6.29） scores vs. （45. 49±6. 32） scores], and significant reductions in NIHSS score [（16. 59±3. 41） scores vs. （13.74±3.18） scores], whole blood high shear viscosity [ （6.27 ±0.51） mPa . s vs. （5.49 ±0.53） mPa . s], whole blood low shear viscosity [（10. 35 ±0.64） mPa . s vs. （9. 28 ±O. 67） mPa . s], hematocrit [（42.37±3.19） % vs. （39.28 ±3.34） %], Fg [ （4. 38 ±0.27） g/L vs. （3.26 ＋ 0.24） g/L] and plasma viscosity [ （1.35 ±0.18） mPa .s vs. （1.19±0. 17） mPa . s] in combined treatment group, P = 0. 001 all. Conclusion： Ginkgo ketoester dispers- ible tablet combined rosiglitazone can effectively improve neurological function and hemodynamics, and improve clinical therapeutic effects in

关 键 词：卒中 罗格列酮 银杏内脂类 

分 类 号：R743.3[医药卫生—神经病学与精神病学]